Literature DB >> 10397612

Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2.

T Tokui1, D Nakai, R Nakagomi, H Yawo, T Abe, Y Sugiyama.   

Abstract

PURPOSE: We previously demonstrated the HMG-CoA reductase inhibitor, pravastatin, is actively taken up into isolated rat hepatocytes through multispecific organic anion transporters. The present study examined whether a newly cloned organic anion transporting polypeptide (oatp2) transports pravastatin.
METHODS: We investigated functional expression of oatp2 in Xenopus laevis oocytes, to examine [14C] pravastatin uptake.
RESULTS: [14C] Pravastatin (30 microM) uptake into oatp2 cRNA-injected oocytes was 40 times higher than that of water-injected control oocytes. The oatp2-mediated pravastatin uptake was Na+-independent and saturable. The Michaelis-Menten constant was 37.5+/-9.9 microM, a level comparable to that obtained in isolated rat hepatocytes in our previous study. As is the case with rat hepatocytes, the uptake of pravastatin (30 microM) was inhibited by 300 microM concentrations of taurocholate, cholate, bromosulfophthalein, estradiol-17beta-glucuronide, and simvastatin acid, but not by para-aminohippurate. On the other hand, [14C] simvastatin acid (30 microM) uptake of oatp2 cRNA-injected oocytes was not significantly different from that of water-injected oocytes.
CONCLUSIONS: The cloned oatp2 was identified as the transporter responsible for the active hepatocellular pravastatin uptake.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10397612     DOI: 10.1023/a:1018838405987

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  26 in total

1.  Expression cloning and characterization of a novel multispecific organic anion transporter.

Authors:  T Sekine; N Watanabe; M Hosoyamada; Y Kanai; H Endou
Journal:  J Biol Chem       Date:  1997-07-25       Impact factor: 5.157

2.  Subunit stoichiometry of a mammalian K+ channel determined by construction of multimeric cDNAs.

Authors:  E R Liman; J Tytgat; P Hess
Journal:  Neuron       Date:  1992-11       Impact factor: 17.173

3.  Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2.

Authors:  T Abe; M Kakyo; H Sakagami; T Tokui; T Nishio; M Tanemoto; H Nomura; S C Hebert; S Matsuno; H Kondo; H Yawo
Journal:  J Biol Chem       Date:  1998-08-28       Impact factor: 5.157

Review 4.  HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.

Authors:  S M Grundy
Journal:  N Engl J Med       Date:  1988-07-07       Impact factor: 91.245

5.  Expression cloning of a rat liver Na(+)-independent organic anion transporter.

Authors:  E Jacquemin; B Hagenbuch; B Stieger; A W Wolkoff; P J Meier
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

6.  Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver.

Authors:  X Bossuyt; M Müller; B Hagenbuch; P J Meier
Journal:  J Pharmacol Exp Ther       Date:  1996-03       Impact factor: 4.030

Review 7.  Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics.

Authors:  M Yamazaki; H Suzuki; Y Sugiyama
Journal:  Pharm Res       Date:  1996-04       Impact factor: 4.200

8.  Tissue-selective action of pravastatin due to hepatocellular uptake via a sodium-independent bile acid transporter.

Authors:  K Ziegler; W Stünkel
Journal:  Biochim Biophys Acta       Date:  1992-07-07

9.  In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.

Authors:  A Saheki; T Terasaki; I Tamai; A Tsuji
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

10.  Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver.

Authors:  M Yamazaki; H Suzuki; M Hanano; T Tokui; T Komai; Y Sugiyama
Journal:  Am J Physiol       Date:  1993-01
View more
  15 in total

Review 1.  Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 2.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

3.  Involvement of organic anion transporting polypeptides in the toxicity of hydrophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibres.

Authors:  K Sakamoto; H Mikami; J Kimura
Journal:  Br J Pharmacol       Date:  2008-05-26       Impact factor: 8.739

4.  Synergistic interaction between genetics and disease on pravastatin disposition.

Authors:  John D Clarke; Rhiannon N Hardwick; April D Lake; Andrew J Lickteig; Michael J Goedken; Curtis D Klaassen; Nathan J Cherrington
Journal:  J Hepatol       Date:  2014-03-05       Impact factor: 25.083

5.  Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure.

Authors:  Feng Li; Mian Zhang; Dan Xu; Can Liu; Ze-Yu Zhong; Ling-Ling Jia; Meng-Yue Hu; Yang Yang; Li Liu; Xiao-Dong Liu
Journal:  Acta Pharmacol Sin       Date:  2014-06       Impact factor: 6.150

6.  SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients.

Authors:  Wei Zhang; Bi-Lian Chen; Vural Ozdemir; Yi-Jing He; Gan Zhou; Dao-Di Peng; Sheng Deng; Qi-Ying Xie; Wei Xie; Lin-Yong Xu; Lian-Ci Wang; Lan Fan; An Wang; Hong-Hao Zhou
Journal:  Br J Clin Pharmacol       Date:  2007-04-18       Impact factor: 4.335

Review 7.  Targeting transporters: promoting blood-brain barrier repair in response to oxidative stress injury.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Brain Res       Date:  2015-03-18       Impact factor: 3.252

Review 8.  Targeted drug delivery to treat pain and cerebral hypoxia.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Pharmacol Rev       Date:  2013-01-23       Impact factor: 25.468

9.  In vitro biliary clearance of angiotensin II receptor blockers and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in sandwich-cultured rat hepatocytes: comparison with in vivo biliary clearance.

Authors:  Koji Abe; Arlene S Bridges; Wei Yue; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2008-06-23       Impact factor: 4.030

10.  UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.

Authors:  Masahide Onoue; Tomohiro Terada; Masahiko Kobayashi; Toshiya Katsura; Shigemi Matsumoto; Kazuhiro Yanagihara; Takafumi Nishimura; Masashi Kanai; Satoshi Teramukai; Akira Shimizu; Masanori Fukushima; Ken-ichi Inui
Journal:  Int J Clin Oncol       Date:  2009-04-24       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.